Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 3—March 2022
Research

Effectiveness of 3 COVID-19 Vaccines in Preventing SARS-CoV-2 Infections, January–May 2021, Aragon, Spain

Alicia del Cura-BilbaoComments to Author , Héctor López-Mendoza, Armando Chaure-Pardos, Alberto Vergara-Ugarriza, and Joaquín Guimbao-Bescós
Author affiliations: Miguel Servet University Hospital, Zaragoza, Spain (A. del Cura-Bilbao); Aragon Department of Health, Zaragoza (A. del Cura-Bilbao, H. López-Mendoza, A. Chaure-Pardos, A. Vergara-Ugarriza, J. Guimbao-Bescós); University of Zaragoza CASSETEM Research Group, Zaragoza (H. López-Mendoza); Lozano Blesa University Hospital, Zaragoza (H. López-Mendoza, A. Chaure-Pardos); GRISSA Research Group, Zaragoza (A. Chaure-Pardos); Aragon Health Research Institute Foundation (IIS Aragon), Zaragoza (A. Chaure-Pardos)

Main Article

Table 1

Characteristics of participants according to vaccination status at endpoint, Aragon, Spain, January–May 2021*

Characteristic Initial cohort population PBNT 1st dose
 PBNT 2nd dose MOD 1st dose MOD 2nd dose
 AZ single dose Unvaccinated
 Lost to follow-up
Age group, y
<25 92,287 (9.6) 1,745 (0.7) 1,489 (0.7) 338 (1.0) 155 (1.0) 3,440 (3.5) 86,764
(14.7)		 1,392 (12.0)
25–49 372,525 (38.6) 19,702
(8.1)		 16,957
(8.0)		 4,230 (13.0) 2,509 (16.0) 19,079 (19.6) 329,514
(55.7)		 3,942 (34.1)
50–74 364,754 (37.8) 110,824 (45.8) 86,764 (40.8) 15,541 (47.8) 2,480 (15.8) 74,939 (76.9) 163,45
(27.6)		 2,497 (21.6)
≥75
 134,692 (14.0)
 109,871 (45.4)
 107,209 (50.5)
 12,413 (38.2)
 10,516 (67.2)
 34
(0.0)
 12,374
(2.1)
 3,726
(32.2)
Sex
F 485,237 (50.3) 143,950 (59.4) 128,280 (60.4) 18,277 (56.2) 10,212 (65.2) 54,132 (55.5) 268,878
(45.4)		 5,986 (51.8)
M
 479,021 (49.7)
 98,192 (40.6)
 84,139 (39.6)
 14,245 (43.8)
 5,448 (34.8)
 43,360 (44.5)
 323,224
(54.6)
 5,571 (48.2)
Site
Rural 354,418 (36.8) 93,723 (38.7) 82,281 (38.7) 5,154 (15.8) 1,373
(8.8)		 35,387 (36.3) 220,154
(37.2)		 4,741 (41.0)
Urban
 609,840 (63.2)
 148,419 (61.3)
 130,138 (61.3)
 27,368 (84.2)
 14,287 (91.2)
 62,105 (63.7)
 371,948
(62.8)
 6,816 (59.0)
Nursing and residential homes
Residents 11,447 (1.2) 10,847 (4.5) 10,431 (4.9) 11 (0.0) 10 (0.1) 7 (0.0) 582 (0.1) 507 (4.4)
Workers
 10,174 (1.1)
 8,734 (3.6)
 8,570 (4.0)
 46 (0.1)
 6 (0.0)
 155 (0.2)
 1,239 (0.2)
 33 (0.3)
Follow-up, mean d (SD)
 133 (34.9)
 15.5 (5.1)
 41 (35.3)
 19.5 (10.4)
 37.9 (23.7)
 30.1 (21.7)
 148.1 (25.2)
 60.1 (33.1)
Total 964,258 (100) 242,142 (100)
 212,419 (100) 32,522 (100) 15,660 (100)
 97,492 (100) 592,102
(100)
 11,557 (100)

*Values are no. (%) participants except as indicated. AZ, Oxford-Astra-Zeneca; MOD, Moderna; PBNT, Pfizer-BioNTech.

Main Article

Page created: December 14, 2021
Page updated: February 21, 2022
Page reviewed: February 21, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external